Eli Lilly and Company $LLY Stake Cut by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 14,485 shares of the company’s stock after selling 525 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Eli Lilly and Company were worth $11,052,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in LLY. Community Trust & Investment Co. lifted its position in Eli Lilly and Company by 2.0% in the 3rd quarter. Community Trust & Investment Co. now owns 24,067 shares of the company’s stock worth $18,363,000 after buying an additional 478 shares in the last quarter. Autumn Glory Partners LLC raised its holdings in shares of Eli Lilly and Company by 60.7% during the third quarter. Autumn Glory Partners LLC now owns 1,678 shares of the company’s stock worth $1,280,000 after acquiring an additional 634 shares in the last quarter. Capital Management Associates Inc boosted its position in Eli Lilly and Company by 4.6% during the third quarter. Capital Management Associates Inc now owns 435 shares of the company’s stock valued at $332,000 after purchasing an additional 19 shares during the last quarter. TI Trust Inc. increased its position in Eli Lilly and Company by 3.9% in the 3rd quarter. TI Trust Inc. now owns 2,239 shares of the company’s stock worth $1,708,000 after purchasing an additional 85 shares during the last quarter. Finally, NJ State Employees Deferred Compensation Plan raised its stake in shares of Eli Lilly and Company by 6.1% during the 3rd quarter. NJ State Employees Deferred Compensation Plan now owns 18,210 shares of the company’s stock worth $13,894,000 after purchasing an additional 1,050 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY opened at $1,107.54 on Thursday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock’s 50 day moving average price is $1,028.26 and its two-hundred day moving average price is $856.98. The firm has a market capitalization of $1.05 trillion, a P/E ratio of 54.18, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,117.66.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 33.86%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. CICC Research boosted their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Leerink Partners set a $1,234.00 price target on Eli Lilly and Company in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Five investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Buy” and a consensus target price of $1,169.00.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly confirmed it will buy Ventyx Biosciences in an all-cash deal worth about $1.2 billion, gaining a pipeline of oral small-molecule NLRP3 inhibitors and inflammatory disease candidates that expand Lilly beyond diabetes/weight-loss. This acquisition is a clear pipeline/strategic positive. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Positive Sentiment: Lilly expanded its obesity/metabolic pipeline via a multiyear partnership/licensing deal with Nimbus (reported value ~$1.3B), adding an oral obesity candidate to its development portfolio — another growth pathway beyond injectables. Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal
• Positive Sentiment: Lilly struck a collaboration with InduPro on a next-gen cancer program worth up to $950 million, strengthening oncology exposure and long-term revenue optionality. Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
• Positive Sentiment: Clarivate named several Lilly cardiometabolic launches among drugs to watch for 2026, highlighting continued product catalysts beyond current blockbusters. Lilly’s prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate
• Positive Sentiment: Analysts are bullish: Citigroup flagged ~50% upside, and several upgrades/positive notes have circulated, supporting momentum and investor confidence in Lilly’s pipeline and earnings outlook. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Neutral Sentiment: The stock printed an all-time high intraday as buyers priced in the M&A and deal flow; that’s market confirmation of the reaction but not a new fundamental. Eli Lilly stock hits all-time high of 1113.03 USD
• Negative Sentiment: Lilly faces legal pressure: the Indiana attorney general sued alleging inflated insulin pricing, a regulatory and reputational overhang that could lead to fines, settlements or policy scrutiny. Indiana sues Eli Lilly alleging insulin price-fixing scheme

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.